Dmitry has joined the company in 2021 as a Chief Scientific Officer and is responsible for all R&D activities of Biodexa Pharmaceuticals. He is a medically trained professional with over 17 years of experience in drug and medical devices development.

Prior to joining Biodexa Pharmaceuticals, Dmitry served as a Chief Medical Officer at Oxford Biomedica plc, a company specialising in development products within the cell & gene area. He has also had roles of increasing responsibilities within GSK, Ono Pharma, Daiichi Sankyo and Grunenthal.

Dmitry holds a MD from the Perm State Medical Academy (Russia), a MBA from the Warwick University and a diploma in pharmaceutical medicine from the Universite Libre de Bruxelles.